<DOC>
<DOCNO>EP-0610357</DOCNO> 
<TEXT>
<INVENTION-TITLE>
TRANSDERMAL THERAPEUTIC SYSTEMS CONTAINING CRYSTALLIZATION INHIBITORS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3156	A61K970	A61K3156	A61K970	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K9	A61K31	A61K9	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
SCHERING AG
</APPLICANT-NAME>
<APPLICANT-NAME>
SCHERING AKTIENGESELLSCHAFT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
LIPP RALPH
</INVENTOR-NAME>
<INVENTOR-NAME>
RIEDL JUTTA
</INVENTOR-NAME>
<INVENTOR-NAME>
TACK JOHANNES
</INVENTOR-NAME>
<INVENTOR-NAME>
LIPP, RALPH
</INVENTOR-NAME>
<INVENTOR-NAME>
RIEDL, JUTTA
</INVENTOR-NAME>
<INVENTOR-NAME>
TACK, JOHANNES
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Transdermal therapeutic system, characterised in that it consists of 

a) a cover layer that is impermeable to water, to penetration enhancer and to 
active ingredient, 
b) an adhesive matrix that adheres to the cover layer and comprises 

b1) one or more active ingredient(s) that crystallise(s) readily and is/are 
insoluble or sparingly soluble in customary adhesive systems, 
b2) a vinylpyrrolidone/vinyl acetate copolymer as crystallisation inhibitor, 
b3) optionally a penetration enhancer, 
c) a removable protective layer. 
Transdermal therapeutic system according to claim 1, characterised in that 
the active ingredient b1) is a steroid hormone. 
</CLAIMS>
</TEXT>
</DOC>
